How Compounding Pharmacies Make Semaglutide and Tirzepatide
A detailed look at the compounding process, from raw ingredient sourcing to the finished medication that arrives at your door.
When you receive a vial of compounded semaglutide or tirzepatide, a rigorous multi-step process has already taken place. Understanding how compounding pharmacies produce these medications can help you feel confident about the product you are using and ask the right questions of your provider.
Step 1: Sourcing Active Pharmaceutical Ingredients (API)
The process begins with procuring pharmaceutical-grade semaglutide or tirzepatide powder, known as the active pharmaceutical ingredient (API). Reputable compounding pharmacies source API exclusively from:
- FDA-registered suppliers based in the United States or verified international facilities
- Suppliers providing Certificates of Analysis (COA) documenting purity (typically 98%+ for peptides), identity confirmation, and absence of contaminants
- USP-grade or equivalent quality raw materials that meet United States Pharmacopeia standards
What a Certificate of Analysis (COA) Includes
- Identity confirmation via HPLC or mass spectrometry
- Purity percentage (peptide content)
- Amino acid sequence verification
- Residual solvent testing
- Heavy metal and endotoxin analysis
- Microbial contamination testing
Step 2: Formulation Development
Before compounding begins, pharmacists develop a precise formulation that specifies the exact amounts of active ingredient, buffers, preservatives, and other excipients needed to create a stable, effective product. This formulation determines:
- Concentration of semaglutide or tirzepatide per milliliter
- Buffer system to maintain proper pH (typically pH 7.0-7.4 for injectables)
- Whether preservatives like benzyl alcohol are included for multi-dose vials
- Tonicity agents to make the solution comfortable for injection
- Beyond-use dating based on stability testing
Step 3: Sterile Compounding in the Cleanroom
Injectable medications must be prepared under strict aseptic conditions to prevent contamination. This is where the cleanroom comes in.
Cleanroom Requirements
- ISO Class 5 environment: Fewer than 3,520 particles per cubic meter of air
- HEPA-filtered laminar airflow hoods: Provide particle-free workspace
- Gowning procedures: Sterile gloves, gowns, masks, shoe covers, and hair covers
- Environmental monitoring: Regular air and surface sampling for microorganisms
- Cleaning protocols: Routine disinfection with sporicidal agents
The compounding process itself follows these steps:
- Weighing: Pharmacists precisely measure the API using calibrated analytical balances accurate to 0.001 grams
- Dissolution: The API is dissolved in sterile water for injection or bacteriostatic water
- Buffer addition: pH buffers are added to achieve the target pH range
- Volume adjustment: The solution is brought to final volume with additional sterile diluent
- Sterile filtration: The solution passes through a 0.22-micron filter to remove any microorganisms
- Filling: Sterile vials are filled with the filtered solution under aseptic conditions
- Sealing and labeling: Vials are sealed with sterile stoppers and aluminum crimps, then labeled
Step 4: Quality Control Testing
Tests Performed on Finished Products
| Test | Purpose | Method |
|---|---|---|
| Potency | Verify correct drug concentration | HPLC analysis |
| Sterility | Confirm no microbial growth | 14-day incubation per USP <71> |
| Endotoxin | Detect bacterial endotoxins | LAL testing per USP <85> |
| pH | Confirm proper acidity | Calibrated pH meter |
| Visual inspection | Check for particulates or discoloration | Light box inspection |
503A vs. 503B: Process Differences
The scale and regulatory framework differ between the two types of compounding pharmacies:
503A pharmacies compound on a per-prescription basis. Each batch is typically small (sometimes a single vial) and is prepared for a specific patient based on their prescription. Quality control may be performed in-house or through contracted labs.
503B outsourcing facilities operate more like small pharmaceutical manufacturers. They produce larger batches, follow current Good Manufacturing Practices (cGMP), are subject to FDA inspections, and perform more extensive quality testing. These facilities can distribute to healthcare facilities and providers without patient-specific prescriptions.
Step 5: Storage and Shipping
Cold Chain Requirements
- Storage: Refrigerated at 36-46 degrees F (2-8 degrees C)
- Shipping: Insulated packaging with cold packs
- Monitoring: Temperature indicators verify cold chain integrity
- Delivery speed: Overnight or 2-day shipping to minimize temperature exposure
Questions to Ask Your Compounding Pharmacy
When evaluating a compounding pharmacy, consider asking these questions:
- Are you a 503A or 503B pharmacy? Are you FDA-registered?
- Where do you source your semaglutide or tirzepatide API?
- Can you provide a Certificate of Analysis for the API?
- What quality testing do you perform on finished products?
- Do you use third-party labs for potency and sterility testing?
- What is the beyond-use date on your compounded products?
- How do you maintain cold chain during shipping?
Conclusion
The process of compounding GLP-1 medications is rigorous and regulated. From sourcing verified pharmaceutical-grade ingredients to sterile cleanroom preparation and multi-point quality testing, legitimate compounding pharmacies follow detailed protocols to produce safe, effective medications. Understanding this process empowers you to ask informed questions and choose a trustworthy provider.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved finished products. Always consult with a qualified healthcare provider before starting any medication.
Get GLP-1 From Verified Pharmacies
Our program partners exclusively with FDA-registered compounding pharmacies for quality you can trust.
Get Started TodayMore on compounding education
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).